Drug Development
Drug Development, News, Syndication, Xconomy »
San Diego’s Receptos, Ambit Biosciences, Get Ready for IPO Debuts |  |
|
Posted by sandiegobiotech May 6th, 2013 .
| |
| No Comments |
[Corrected 5/6/13, 10:50 am. See below.] San Diego-based Receptos, a biotech developing new treatments for immune disorders, is among 13 IPOs expected to go public this week, according to Renaissance…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
Abide Therapeutics and Merck Unveil Diabetes Drug Collaboration | |
|
Posted by sandiegobiotech May 2nd, 2013 .
| |
| No Comments |
Abide Therapeutics, a two-year-old San Diego biopharmaceutical firm pioneering new ways to identify and validate drug targets among the serine hydrolase “superfamily” of enzymes, says today it has…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs | |
|
Posted by sandiegobiotech April 8th, 2013 .
| |
| No Comments |
San Diego-based Ambrx says it’s getting an upfront payment of $15 million under a deal with Japan’s Astellas to help develop an undisclosed number of targets for antibody drug conjugates in cancer….
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Still Waiting for the Ships to Come in at Third Rock Ventures | |
|
Posted by sandiegobiotech March 28th, 2013 .
| |
| No Comments |
Third Rock Ventures was in the enviable position of turning away some institutional investors when the life sciences venture firm recently closed on $516 million for its third venture fund. So first…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
New Domain Partnership Focuses on China’s Emerging Healthcare Market | |
|
Posted by sandiegobiotech March 13th, 2013 .
| |
| No Comments |
Domain Associates, the life sciences venture firm based in San Diego and Princeton, NJ, says today it has formed a partnership with the Beijing-based firm Elite Consulting to license biomedical…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
Sophiris Bio Files $75M IPO, Plans Pivotal Trials of Prostate Drug | |
|
Posted by sandiegobiotech February 19th, 2013 .
| |
| No Comments |
San Diego-based Sophiris Bio, which was founded in Vancouver B.C. and already trades on the Toronto Stock Exchange, intends to list its shares on the Nasdaq and raise almost $75 million through an…
[[Click headline to continue reading.]]
More...
